Navigation Links
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc.
Date:1/15/2014

LAVAL, Quebec, Jan. 15, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to the previously announced tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all of the outstanding shares of common stock of Solta Medical, Inc. (NASDAQ: SLTM) ("Solta") at a price of $2.92 per share, net to the seller in cash, without interest (less any required withholding taxes) and subsequent merger of Purchaser with Solta expired at 11:59 p.m., New York City time on January 14, 2014.  The expiration of the HSR waiting period satisfies one of the conditions to consummate the tender offer.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward-Looking Statements

This press release may contain forward-looking statements regarding, among other things, the proposed acquisition by Valeant of Solta and expected timing of the transaction.  Because these statements reflect Valeant's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties.  Investors should note that many factors could affect the proposed business combination of the
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan
2. Valeant Pharmaceuticals To Present At Industry Conferences
3. Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash
4. Valeant Pharmaceuticals Announces Redemption Of The Remaining $465.5 Million Aggrerate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes
6. Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
7. Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
8. Valeant Pharmaceuticals Announces Settlement Agreement With Anacor
9. Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence
10. Valeant Pharmaceuticals Announces Continuance
11. Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical company ... in the U.S. and XIAPEX ® in the ... will present at the following upcoming investor conferences. ... Renshaw 16 th Annual Global Investment Conference ( ... at 9:10 a.m. EDT , Aegis Capital 2014 ...
(Date:9/2/2014)... 2, 2014  MEI Pharma, Inc. (Nasdaq: ... the clinical development of novel therapies for cancer, ... a randomized Phase II clinical trial of its ... azacitidine in patients with previously untreated intermediate-2 or ... study enrolled a total of 108 patients with ...
(Date:9/2/2014)... SAN ANTONIO , Sept. 2, 2014 /PRNewswire/ ... private medical technology company focused on innovating lifesaving ... announced the appointment of Dr. Gabriele Niederauer ... President and CEO. Following the recent closure of ... CE Mark for the Surfacer™ Inside-Out Access Catheter ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 2MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 3MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 4Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO 2
... Inc. ( www.hydrocision.com ), a privately held medical ... majority of the Company by new investors, led ... Omega Funds. HydroCision is the developer, manufacturer, and ... allows discectomy and interbody fusion procedures to be ...
... CITY, Sept. 15 Amedica Corporation, a spinal and ... nitride (SiN) ceramic technologies, announced today that it has ... disc replacement (TDR) technology that features the use of ...  U.S. Patent No. 7,758,646 B2 and U.S. Patent No. ...
Cached Medicine Technology:HydroCision Announces New Investment to Accelerate Growth of Novel Fluidjet Technology for Minimally Invasive Spine Surgery 2Amedica® Receives Patents for Innovative Motion-Preserving Total Disc Implant Featuring Silicon Nitride 2
(Date:9/2/2014)... in Spanish . ... an experiment conducted on rats, that hyperproteic diets could be ... groups with bone disease problems, such as the elderly or ... proteinin the case of the present study, soy proteinis preferable ... increased the level of calcium in bones by as much ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 According ... http://www.idataresearch.com ), the leading global authority in medical ... market is expected to grow to over ... by an increase in the number of procedures ... kidney stones. This market includes TURP devices, laser ...
(Date:9/2/2014)... Splashtop Inc. , the worldwide leader ... NTT DoCoMo to deliver Splashtop Business Lite for ... is included in NTT DoCoMo’s “Business Plus” program. , ... empower users to remote access their corporate computers from ... million users worldwide. Splashtop delivers the best in ...
(Date:9/2/2014)... Medical Goods manufacture ThermoTek , announced today a ... Inc. to help customers acquire capital goods faster and ... finance shopping platform has enabled businesses to quickly and ... business. , Said LeaseQ Vice President Cory Damm, ... to provide customers faster access to capital and allow ...
(Date:9/2/2014)... September 02, 2014 Based on ... used during hysterectomy, kidney and spleen surgeries, have ... cells and harm patients. , An article ... Michael A. Seidman, Titilope Oduyebo and Bradley J. ... Mesenchymal Neoplasms" published on Nov 26, 2012 defines ...
Breaking Medicine News(10 mins):Health News:Study conducted on rats suggests that hyperproteic diets can be beneficial for bones 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Splashtop and NTT DoCoMo Partner to Deliver “Splashtop Business Lite” Secure Remote Access Solution to Business Customers 2Health News:Medical Technology Manufacturer ThermoTek Announces New Partnership with LeaseQ.com to Help More Customers Acquire Equipment Faster and Cheaper 2Health News:New York Law Firm Discusses Allegedly Dangerous Surgical Morcellator Devices And Cancer Risk 2Health News:New York Law Firm Discusses Allegedly Dangerous Surgical Morcellator Devices And Cancer Risk 3
... HealthDay Reporter , TUESDAY, Aug. 24 (HealthDay News) -- ... by a U.S. judge to halt any expansion ... temporary injunction, which basically blindsided the scientific community, effectively ... days. That was when then-President Bush ordered that federal ...
... people lose weight and body fat when they exercise and eat ... (MR) spectroscopy can provide the answer and help predict who ... online and will appear in the November issue of the journal ... the same and have the same body mass index (BMI), but ...
... HealthDay Reporter , TUESDAY, Aug. 24 (HealthDay News) -- ... a day boost a woman,s odds of premature delivery? ... The researchers looked at the soft drink habits of ... from 1996 to 2002. The investigators found a link ...
... 2010 The Joint Commission has certified UT Southwestern ... Center, a distinction for hospitals fostering specialized stroke care ... imaging specialists, nurses and technicians have ready access to ... or after a stroke. Each year about 700,000 people ...
... breast imaging exams may increase a woman,s risk of ... online and in the October issue of Radiology ... are very low. "A single breast-specific gamma imaging ... lifetime risk of inducing fatal cancer greater than or ...
... 2010) While success is surely sweeter than failure, it ... fail spectacularly often flourish more in the long run, ... of management at the University of Colorado Denver Business School. ... Journal , focused on companies and organizations that launch satellites, ...
Cached Medicine News:Health News:Scientists Dismayed by Stem Cell Research Ruling 2Health News:Scientists Dismayed by Stem Cell Research Ruling 3Health News:Fat distribution plays a role in weight loss success in patients at risk of diabetes 2Health News:Study Suggests Link Between Diet Sodas, Preterm Delivery 2Health News:Study Suggests Link Between Diet Sodas, Preterm Delivery 3Health News:UT Southwestern University Hospital -- St. Paul recognized as Primary Stroke Center 2Health News:UT Southwestern University Hospital -- St. Paul recognized as Primary Stroke Center 3Health News:New nuclear breast imaging technologies associated with higher cancer risks 2Health News:New nuclear breast imaging technologies associated with higher cancer risks 3Health News:University of Colorado Denver Business School study shows failure better teacher than success 2
Rapid reagent impregnated disk test for presumptive identification of Candida albicans....
... Electronic Medical Records for small and large ... from check-in to check-out. Review the complete ... medications, to allergies, labs and charts all ... your patient records immediately. Communicate electronically with ...
... Written specifically for urologists by ... utilizes touch screen technology to ... eliminate the use of a ... makes using an EMR faster ...
... a new generation of advanced Electronic Medical ... the largest, numerically codified medical vocabularies in ... data elements embedded in MedcomSoft Record, healthcare ... an easy and intuitive point and click ...
Medicine Products: